[go: up one dir, main page]

WO2000053628A3 - Genes encoding human potassium channel proteins - Google Patents

Genes encoding human potassium channel proteins Download PDF

Info

Publication number
WO2000053628A3
WO2000053628A3 PCT/EP2000/001750 EP0001750W WO0053628A3 WO 2000053628 A3 WO2000053628 A3 WO 2000053628A3 EP 0001750 W EP0001750 W EP 0001750W WO 0053628 A3 WO0053628 A3 WO 0053628A3
Authority
WO
WIPO (PCT)
Prior art keywords
genes encoding
potassium channel
encoding human
channel proteins
human potassium
Prior art date
Application number
PCT/EP2000/001750
Other languages
French (fr)
Other versions
WO2000053628A2 (en
Inventor
David Malcolm Duckworth
Robert James Godden
Conrad Gerald Chapman
Helen Jane Meadows
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9905061.9A external-priority patent/GB9905061D0/en
Priority claimed from GB0003112A external-priority patent/GB0003112D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Priority to JP2000604063A priority Critical patent/JP2002542765A/en
Priority to EP00910744A priority patent/EP1165777A2/en
Publication of WO2000053628A2 publication Critical patent/WO2000053628A2/en
Publication of WO2000053628A3 publication Critical patent/WO2000053628A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)

Abstract

DKCN1 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing DKCN1 polypeptides and polynucleotides in diagnostic assays.
PCT/EP2000/001750 1999-03-05 2000-03-02 Genes encoding human potassium channel proteins WO2000053628A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2000604063A JP2002542765A (en) 1999-03-05 2000-03-02 New compound
EP00910744A EP1165777A2 (en) 1999-03-05 2000-03-02 Genes encoding human potassium channel proteins

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9905061.9A GB9905061D0 (en) 1999-03-05 1999-03-05 Novel compounds
GB9905061.9 1999-03-05
GB0003112.0 2000-02-10
GB0003112A GB0003112D0 (en) 2000-02-10 2000-02-10 Novel compounds

Publications (2)

Publication Number Publication Date
WO2000053628A2 WO2000053628A2 (en) 2000-09-14
WO2000053628A3 true WO2000053628A3 (en) 2000-12-21

Family

ID=26243623

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/001750 WO2000053628A2 (en) 1999-03-05 2000-03-02 Genes encoding human potassium channel proteins

Country Status (3)

Country Link
EP (1) EP1165777A2 (en)
JP (1) JP2002542765A (en)
WO (1) WO2000053628A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5079401A (en) * 2000-03-03 2001-09-17 Tularik Inc Kcnb: a novel potassium channel protein
WO2005075510A1 (en) * 2004-02-04 2005-08-18 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with potassium channel, subfamily k, member 9 (kcnk9)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000000610A2 (en) * 1998-06-26 2000-01-06 Incyte Pharmaceuticals, Inc. Human signal peptide-containing proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000000610A2 (en) * 1998-06-26 2000-01-06 Incyte Pharmaceuticals, Inc. Human signal peptide-containing proteins

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ADAMS, M.D. ET AL.: "3,400 new expressed sequence tags identify diversity of transcripts in human brain", NATURE GENETICS, vol. 4, no. 3, July 1993 (1993-07-01), pages 256 - 267, XP000611495 *
EMBL Database, Heidelberg, FRG Emest_Hum20 accession number AA349574 18 April 1997 ADAMS, M.D. ET AL.: "EST56307 Infant brain Homo sapiens cDNA 3' end, mRNA sequence" *
EMBL Database, Heidelberg, FRG Emhtg1 accession number AC008495 04 August 1999 DOE JOINT GENOME INSTITUTE: "Homo sapiens chromosome 5 clone CTC-431C18, WORKING DRAFT SEQUENCE, 12 ordered pieces" *
LEONOUDAKIS, D. ET AL.: "An Open Rectifier Potassium Channel with Two Pore Domains in Tandem Cloned from Rat Cerebellum", JOURNAL OF NEUROSCIENCE, vol. 18, no. 3, 1 February 1998 (1998-02-01), pages 868 - 877, XP002146307 *
RAJAN, S. ET AL.: "TASK-3, a Novel Tandem Pore Domain Acid-Sensitive K1 Channel. An Extracellular Histidine as pH Sensor", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 22, 2 June 2000 (2000-06-02), pages 16650 - 16657, XP002146308 *

Also Published As

Publication number Publication date
JP2002542765A (en) 2002-12-17
WO2000053628A2 (en) 2000-09-14
EP1165777A2 (en) 2002-01-02

Similar Documents

Publication Publication Date Title
EP1001023A3 (en) Frizzled-4, a putative Wnt-receptor
EP0939124A3 (en) MGBP1 sequences
WO2002059315A3 (en) Human nucleic acids and polypeptides and methods of use thereof
WO2001004141A3 (en) Seripancrin
WO1999035266A3 (en) Human urotensin ii
EP0885959A3 (en) Human Wnt-5b protein
EP0879888A3 (en) Patched-2 polypeptides and polynucleotides and methods for their production
WO2001032864A3 (en) Gpcr-kd5 polypeptides and dna sequences thereof
WO2001083744A3 (en) Natrium-calcium exchanger protein
EP0943684A3 (en) Frizzled-like polypeptides and polynucleotides
WO2000053628A3 (en) Genes encoding human potassium channel proteins
EP0887416A3 (en) Human AFC1
DE60117788D1 (en) HUMAN WINGLESS-ENOUGH GENES
WO2001068816A8 (en) Human histamine h3 gene variant-3
EP0937777A3 (en) GABA receptors and their uses
WO1999011783A3 (en) T-box polypeptides
WO2002046408A3 (en) Human proteins, polynucleotides encoding them and methods of using the same
EP0890646A3 (en) HE2NW40 Serine Protease
EP0887415A3 (en) Human RCE1
WO1999038885A3 (en) Sbsemvl polypeptides, being members of the semaphorin protein family, and polynucleotides encoding the same
EP0969091A3 (en) Leptin receptor gene-related protein
WO2001068703A8 (en) Human histamine h3 gene variant-2
WO2001083771A3 (en) Human phospholipase c delta 5
EP0875570A3 (en) Neurodegenerative polypeptides HHPDZ65
WO2001079269A3 (en) Lipid binding protein 4

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 604063

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000910744

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000910744

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000910744

Country of ref document: EP